Emergent BioSolutions (EBS) Announces Proposed Offering Of $200 Million Convertible Senior Notes
1/23/2014 9:54:59 AM
ROCKVILLE, Md.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (“Emergent”) (NYSE: EBS) announced today that it intends to offer, subject to market and other conditions, $200 million aggregate principal amount of Convertible Senior Notes due 2021 (the “Notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Emergent also intends to grant the initial purchasers an option to purchase up to an additional $30 million aggregate principal amount of the Notes.
Help employers find you! Check out all the jobs and post your resume.
comments powered by